An update on diabetic kidney disease, oxidative stress and antioxidant agents

Mahmoodnia, Leila; Aghadavod, Esmat; Beigrezaei, Sara; Rafieian-Kopaei, Mahmoud

doi:10.15171/jrip.2017.30

Cited by 47 publications

(31 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxidative stress plays an essential role in the pathogenesis of different types of CKD, especially in diabetic nephropathy. Hyperglycemia induces autoxidation of glucose and glycosylation of proteins by the generation of reactive oxygen species, and increases oxidative stress[ 36 ]. Here, we have observed that coagonist increased SOD and CAT activity, and reduced TBARS content in kidney.…”

Section: Discussionmentioning

confidence: 99%

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus

Patel¹,

Joharapurkar²,

Kshirsagar³

et al. 2018

WJD

View full text Add to dashboard Cite

AIMTo investigate the role of glucagon-like peptide-1 (GLP-1)/glucagon receptors coagonist on renal dysfunction associated with diabetes and obesity.METHODSChronic high-fat diet fed C57BL/6J mice, streptozotocin-treated high-fat diet fed C57BL/6J mice and diabetic C57BLKS/J db/db mice were used as models of diabetes-induced renal dysfunction. The streptozotocin-treated high-fat diet fed mice and db/db mice were treated with the GLP-1 and glucagon receptors coagonist (Aib2 C24 Chimera2, 150 μg/kg, sc) for twelve weeks, while in chronic high-fat diet fed mice, coagonist (Aib2 C24 Chimera2, 150 μg/kg, sc) treatment was continued for forty weeks. Kidney function, histology, fibrosis, inflammation, and plasma biochemistry were assessed at the end of the treatment.RESULTSCoagonist treatment decreased body weight, plasma lipids, insulin resistance, creatinine, blood urea nitrogen, urinary albumin excretion rate and renal lipids. In kidney, expression of lipogenic genes (SREBP-1C, FAS, and SCD-1) was decreased, and expression of genes involved in β-oxidation (CPT-1 and PPAR-α) was increased due to coagonist treatment. In plasma, coagonist treatment increased adiponectin and FGF21 and decreased IL-6 and TNF-α. Coagonist treatment reduced expression of inflammatory (TNF-α, MCP-1, and MMP-9) and pro-fibrotic (TGF-β, COL1A1, and α-SMA) genes and also improved histological derangement in renal tissue.CONCLUSIONCoagonist of GLP-1 and glucagon receptors alleviated diabetes and obesity-induced renal dysfunction by reducing glucose intolerance, obesity, and hyperlipidemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus

Patel¹,

Joharapurkar²,

Kshirsagar³

et al. 2018

WJD

View full text Add to dashboard Cite

show abstract

“…In these complications, diabetic nephropathy is the main one which could lead to kidney failure [ 3 ]. Diabetic kidney disease is one of the critical problems of diabetes mellitus in which the prevalence has been increasing worldwide [ 4 ]. Diabetic nephropathy is a unique predictor of mortality in both insulin-dependent and insulin-independent diabetes [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy

Pan¹,

et al. 2018

Disease Markers

View full text Add to dashboard Cite

It would be important to predict type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN). This study was aimed at evaluating the predicting significance of hemostatic parameters for T2DM and DN. Plasma coagulation and hematologic parameters before treatment were measured in 297 T2DM patients. The risk factors and their predicting power were evaluated. T2DM patients without complications exhibited significantly different activated partial thromboplastin time (aPTT), platelet (PLT), and D-dimer (D-D) levels compared with controls (P < 0.01). Fibrinogen (FIB), PLT, and D-D increased in DN patients compared with those without complications (P < 0.001). Both aPTT and PLT were the independent risk factors for T2DM (OR: 1.320 and 1.211, P < 0.01, resp.), and FIB and PLT were the independent risk factors for DN (OR: 1.611 and 1.194, P < 0.01, resp.). The area under ROC curve (AUC) of aPTT and PLT was 0.592 and 0.647, respectively, with low sensitivity in predicting T2DM. AUC of FIB was 0.874 with high sensitivity (85%) and specificity (76%) for DN, and that of PLT was 0.564, with sensitivity (60%) and specificity (89%) based on the cutoff values of 3.15 g/L and 245 × 109/L, respectively. This study suggests that hemostatic parameters have a low predicting value for T2DM, whereas fibrinogen is a powerful predictor for DN.

show abstract

“…Recent studies show that diabetes develops “oxidative stress.” Due to the reduction of antio-xidant status production of free radicals increases, enzymatic disorders that largely determine the secondary organ complications from diabetes [ 50 ]. Even with a normal level of LOW DENSITY LIPO-PROTEIN (LDL) there may be detectable markers of oxidation, such as antibodies to oxidized LDL and LDL-containing immune complexes, which seems a predisposing factor for the development of coronary artery lesions [ 51 ].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Apheresis in Metabolic Syndrome

Voinov

2018

IEMAMC

View full text Add to dashboard Cite

Background:The metabolic syndrome unites three pathologies of the person – obesity, arterial hypertension and diabetes. In recent years the progressing of such distribution covering from 2.5% to 3.8% of the population with increase twice each 10-15 years is noted. Even at maintenance of level of sugar at diabetes accumulation of the secondary metabolites breaking small vessels isn't excluded. At the same time many life-endangering complications develop.Objective:To identify the possibilities of plasmapheresis in the prevention and treatment of complications of metabolic syndrome.Method:Analysis of the world literature data on complications of metabolic syndrome and methods of their treatment.Results:At metabolic syndrome the frequency of strokes and myocardial infarctions there is twice more often than in population. For 5-9 years the general life expectancy decreases. Disorders of microcirculation at diabetes lead to a retinopathy with total loss of sight, a nephropathy from the outcome in a renal failure, to polyneuropathy and diabetic foot syndrome with high risk of high level amputations of the lower extremities. At the same time medicamentous therapy is not able to prevent such complications and almost only way of removal of these pathological metabolites is therapeutic apheresis, mainly the plasmapheresis. Data from our own studies confirm the effectiveness of such tactics.Conclusion:Plasmapheresis has to be applied not only to the correction of already critical conditions, but also to their prevention.

show abstract

An update on diabetic kidney disease, oxidative stress and antioxidant agents

Cited by 47 publications

References 31 publications

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus

Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy

Therapeutic Apheresis in Metabolic Syndrome

Contact Info

Product

Resources

About